Abstract. Somatostatin 
and delivery. There was a marked decrease in cord blood thyrotrophin (TSH) (Siler et al. 1973; Hall et al. 1973 ; Prange-Hansen et al. 1973; Mortimer et al. 1974; Parker et al. 1974 ). Thyrotrophin (TSH) secretion is also de¬ creased by the administration of SRIF. This inhibi¬ tory effect of SRIF on TSH secretion has been observed in normal, hypothyroid or thyrotrophin releasing hormone (TRH) treated subjects or in patients with TSH producing pituitary tumours (Morley 1981; Reschini et al. 1976 ). In the rat, the administration of SRIF antiserum results in an increase in both GH and TSH concentrations in serum, suggesting that SRIF has a physiological role in the control of GH and TSH secretion (Morley 1981) .
We have recently reported that TRH admini¬ stered to the mother crosses the placenta and stimulates foetal TSH secretion (Roti et al. 1981a (Gluckman et al. 1979 ) and does not alter the secretion of hCG or hPL in vitro from human placentas (Macaron et al. 1978 ). T3, rT3 and hTg concentrations in serum were measured by radioimmunoassay. The sensitivity of the various RIA's are: GH, 0.25 ng/ml; TSH, 0.6 µ /ml; Tg, 2.5 ng/ml; T4, 0.6 µg/dI; T3, 6.2 ng/dl; rT3, 2.5 ng/dl. All samples were measured in duplicate, in the same assay and in random order.
For evaluation of the maternal results, MS of women treated with saline were assigned to group 0. Sera from women treated with SRIF were assigned to four groups, 1 to 4, depending on the interval of time between the end of SRIF infusion and parturition. Statistical Concentrations of T4, T3, rT3, hTg, TSH, GH and blood glucose in MS samples before (basal) and after (treated) saline infusion (group 0) or SRIF infusion (groups 1 to 4). (Fig. 2) . In groups 1, 2 and 3, CB TSH (Parker et al. 1974 ) and the nocturnal TSH elevation (Weeke et al. 1975 ) in normal subjects. The failure of SRIF to inhibit basal maternal TSH concentrations is also in ac¬ cord with the observation that the addition of SRIF in vitro does not block the release of TSH into the medium from primary cultures of rat anterior pituitary cells or hemipituitaries (Vale et al. 1974; Drouinetal. 1976) .
In previous studies, we have demonstrated that TRH crosses the placental barrier and stimulates the release of TSH and GH from the human foetal pituitary (Roti et al. 1981a (Roti et al. , 1982 . In the present study we (Weeke et al. 1975) .
Our findings in man are consistent with previous observations in the foetal sheep. In chronically catheterized foetuses, the infusion of synthetic SRIF has been reported to decrease GH secretion (Gluckman et al. 1979) . Similar effects were also observed during the neonatal period (Gluckman et al. 1979 ). Furthermore, it has been observed that SRIF administration to newborn sheep prevents the TSH release induced by TRH administration (Sack et al. 1977) . In humans, the administration of SRIF during the early postnatal period has been reported to decrease serum GH concentration (Delitala et al. 1978) . Similar results have been obtained with human foetal pituitary glands stud¬ ied in vitro. Human foetal pituitaries obtained at 10 to 19 weeks of pregnancy incubated in the presence of SRIF at concentrations of 2 x 10~5 to 10"9 markedly reduced GH release into the medium (Goodyer et al. 1977) . The presence of SRIF in the human hypothalamus has been observed by detect¬ ing SRIF by radioimmunoassay in tissue extracts obtained from foetuses of 10 to 22 weeks of gestation (Aubert et al. 1977 (Oliver et al. 1982) .
SRIF has been detected in the human decidua, placenta and amniotic fluid (Kumasaka et al. 1979; Fitz-Patrick & Patel 1979 
